Monument Capital Management Purchases 50 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Monument Capital Management lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 853 shares of the medical research company’s stock after acquiring an additional 50 shares during the quarter. Monument Capital Management’s holdings in Thermo Fisher Scientific were worth $453,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. International Assets Investment Management LLC boosted its position in shares of Thermo Fisher Scientific by 43.5% in the third quarter. International Assets Investment Management LLC now owns 1,626 shares of the medical research company’s stock valued at $810,000 after acquiring an additional 493 shares during the period. Arkadios Wealth Advisors boosted its position in shares of Thermo Fisher Scientific by 33.3% in the third quarter. Arkadios Wealth Advisors now owns 896 shares of the medical research company’s stock valued at $454,000 after acquiring an additional 224 shares during the period. Wedge Capital Management L L P NC boosted its position in shares of Thermo Fisher Scientific by 8.3% in the third quarter. Wedge Capital Management L L P NC now owns 740 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 57 shares during the period. Summit Global Investments lifted its position in Thermo Fisher Scientific by 27.8% during the third quarter. Summit Global Investments now owns 1,392 shares of the medical research company’s stock valued at $704,000 after purchasing an additional 303 shares during the last quarter. Finally, Naples Global Advisors LLC lifted its position in Thermo Fisher Scientific by 37.3% during the third quarter. Naples Global Advisors LLC now owns 755 shares of the medical research company’s stock valued at $382,000 after purchasing an additional 205 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,277 shares of company stock worth $28,513,384. Corporate insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on TMO shares. HSBC lifted their target price on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. The Goldman Sachs Group lifted their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Stock Up 0.7 %

Shares of Thermo Fisher Scientific stock opened at $548.37 on Tuesday. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $571.30 and its two-hundred day simple moving average is $528.18. The company has a market cap of $209.32 billion, a P/E ratio of 35.49, a PEG ratio of 2.30 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the previous year, the firm earned $5.40 EPS. The company’s quarterly revenue was down 4.9% compared to the same quarter last year. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.